Results 81 to 90 of about 54,210 (294)
Arthritis &Rheumatology, EarlyView.Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller +16 more
wiley +1 more source
Chronic Brucella infection associated with amyloid light chain cardiac amyloidosis: a case report
Frontiers in Cardiovascular MedicineBackgroundAmyloidosis is a rare group of diseases characterized by extracellular deposition of amyloid fibrils. The most common types are amyloid light chain (AL) and transthyretin (ATTR), while serum amyloid A (AA) type is relatively rare.
RuiXia He +8 more
doaj +1 more source
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
British Journal of Clinical Pharmacology, EarlyView.Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source
A Rare Case: Primary Pulmonary Amyloidosis
Düzce Tıp Fakültesi DergisiAmyloidosis is a rare disorder characterized by the extracellular deposition of insoluble protein aggregates. There are two common types of amyloidosis: Amyloid A (AA) and amyloid light chain (AL).
Ceyda Ceylan +3 more
doaj +1 more source
An unusual case of chronic lymphocytic leukemia, multiple myeloma and cardiac amyloidosis
Journal of Community Hospital Internal Medicine Perspectives, 2017 Light chain amyloidosis has very rarely been reported in association with chronic lymphocytic leukemia (CLL). We reported on a 76-years-old female who presented with simultaneous kappa-restricted chronic lymphocytic leukemia (CLL) and a lambda-restricted
Dongyan Liu +2 more
doaj +1 more source
Systemic amyloidosis in England: an epidemiological study.
, 2013 Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Smith, CJ +11 more
core
British Journal of Clinical Pharmacology, EarlyView.Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen +8 more
wiley +1 more source
Annals of Internal Medicine: Clinical CasesLight chain (AL) amyloidosis involves deposition of monoclonal immunoglobulin light chain-derived amyloid fibrils, whereas ATTR amyloidosis involves deposition of insoluble antiparallel beta-pleated protein within tissues, leading to organ-specific ...
Robert A. Churchill, Andrew Rosenbaum
doaj +1 more source
F1000Research, 2018 Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction.
Talha Badar +2 more
doaj +1 more source
Monoclonal IgM-related AL amyloidosis
, 2016 Monoclonal immunoglobulin M (IgM)-related light chain (AL) amyloidosis, which accounts for 5%–7% of all AL amyloidosis cases, is a distinct clinical entity that poses specific challenges to clinicians.
Milani P., Merlini G.
core +1 more source